Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hjelmström

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Lakartidningen|May 25, 2002
[Chemokines a hope of specific anti-inflammatory treatment]Per Schedvins, Peter Hjelmström
Drug Development and Industrial Pharmacy|October 9, 2013
Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteersAndreas Fischer, Martin Jönsson, Peter Hjelmström
Clinical Therapeutics|September 29, 2015
Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trialErik W Gunderson, Peter Hjelmström, Michael Sumner, et al.
Drug Development and Industrial Pharmacy|January 10, 2020
Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy dataPeter Hjelmström, Elin Banke Nordbeck, Fredrik Tiberg
Addiction (Abingdon, England)|June 14, 2020
Methadone-related deaths among youth and young adults in Sweden 2006-15Anna Fugelstad, Sven Bremberg, Peter Hjelmström, et al.
Journal of Addictive Diseases|June 9, 2016
Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trialLynn Webster, Peter Hjelmström, Michael Sumner, et al.
Journal of Neuroimmunology|June 30, 2004
Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosisMathula Thangarajh, Andreia Gomes, Thomas Masterman, et al.
Drug and Alcohol Dependence|March 20, 2022
Oxycodone-related deaths in Sweden 2006-2018Anna Fugelstad, Gunnar Ågren, Mats Ramstedt, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 19, 2007
Increased CD8+ central memory T cells in patients with multiple sclerosisGuang-Zhi Liu, Li-Bo Fang, Peter Hjelmström, et al.
International Journal of Molecular Medicine|October 9, 2003
Genotypes of CCR2 and CCR5 chemokine receptors in human myasthenia gravisXiaoyan Zhao, Baback Gharizadeh, Peter Hjelmström, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Lakartidningen|May 25, 2002
[Chemokines a hope of specific anti-inflammatory treatment]Per Schedvins, Peter Hjelmström
Drug Development and Industrial Pharmacy|October 9, 2013
Pharmaceutical and pharmacokinetic characterization of a novel sublingual buprenorphine/naloxone tablet formulation in healthy volunteersAndreas Fischer, Martin Jönsson, Peter Hjelmström
Clinical Therapeutics|September 29, 2015
Effects of a higher-bioavailability buprenorphine/naloxone sublingual tablet versus buprenorphine/naloxone film for the treatment of opioid dependence during induction and stabilization: a multicenter, randomized trialErik W Gunderson, Peter Hjelmström, Michael Sumner, et al.
Drug Development and Industrial Pharmacy|January 10, 2020
Optimal dose of buprenorphine in opioid use disorder treatment: a review of pharmacodynamic and efficacy dataPeter Hjelmström, Elin Banke Nordbeck, Fredrik Tiberg
Addiction (Abingdon, England)|June 14, 2020
Methadone-related deaths among youth and young adults in Sweden 2006-15Anna Fugelstad, Sven Bremberg, Peter Hjelmström, et al.
Journal of Addictive Diseases|June 9, 2016
Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trialLynn Webster, Peter Hjelmström, Michael Sumner, et al.
Journal of Neuroimmunology|June 30, 2004
Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosisMathula Thangarajh, Andreia Gomes, Thomas Masterman, et al.
Drug and Alcohol Dependence|March 20, 2022
Oxycodone-related deaths in Sweden 2006-2018Anna Fugelstad, Gunnar Ågren, Mats Ramstedt, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 19, 2007
Increased CD8+ central memory T cells in patients with multiple sclerosisGuang-Zhi Liu, Li-Bo Fang, Peter Hjelmström, et al.
International Journal of Molecular Medicine|October 9, 2003
Genotypes of CCR2 and CCR5 chemokine receptors in human myasthenia gravisXiaoyan Zhao, Baback Gharizadeh, Peter Hjelmström, et al.
Pageof 2